The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Diogo Martins-BrancoMarie KassapianVeronique DebienRafael CaparicaDaniel EigerUrania DafniCharitini AndriakopoulouSarra El-AbedSusan L EllardMiguel IzquierdoMalou VicenteSaranya ChumsriMartine J PiccartAlvaro Moreno-AspitiaAnn Søegaard KnopJanine LombardEvandro de AzambujaPublished in: Breast cancer research and treatment (2023)
ESA administration to patients receiving adjuvant anti-HER2 treatment for HER2-positive EBC was safe and not associated with a negative impact on survival outcomes.